Yükleniyor... / Loading...
This study examines the safety and effectiveness of ZVS203e, a gene therapy, in treating retinitis pigmentosa caused by the RHO (c.403C>T, p.R135W) gene mutation. It enrolls people aged 18 and older with retinitis pigmentosa whose mutation has been confirmed by genetic testing. It is in Phase 1/Phase 2 and is currently recruiting.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Patients with a clinical diagnosis of retinitis pigmentosa (RP) (aged 18 years or older); 2. RHO (c.403C\>T, p.R135W) gene site-specific mutation was confirmed by genetic testing, and no other ophthalmic genetic diseases were complicated; 3. The researchers judged that the target eye had viable retinal photoreceptor cells and retinal pigment epithelial cells; 4. The best corrected visual acuity of the target eye is between 2.0 LogMAR and 0.5 LogMAR (including 2.0 LogMAR and 0.5 LogMAR, which is equivalent to a number of fingers to 60 letters); 5. The subject and his or her spouse agree to use effective contraception during the trial period and for at least 1 year after dosing; 6. Voluntarily participate in clinical trials and sign informed consent, and can complete the whole test process according to the protocol requirements. Exclusion Criteria: 1. The researcher determined that the target eye currently has or had macular lesions such as macular hiatal hole or macular neovascularization; 2. Have other eye conditions that may prevent surgery or interfere with interpretation of the study endpoint, such as glaucoma, diabetic retinopathy, eye or periocular infections, active endophthalmitis, etc. 3. Within 3 months prior to enrollment, the study eye had received any intraocular surgery, such as phacoemulsification cataract extraction. 4. The study eye had undergone retinal reattachment or vitrectomy. 5. Participants who had participated in any drug or medical device clinical trial within 3 months before enrollment; 6. Previously treatment of either eye with gene therapy or stem cell therapy for RP and other ocular diseases, including but not limited to viral vector gene therapy, RNA therapy. 7. Treatment with medications that may affect the efficacy and safety evaluation of the investigational product within 3 months prior to enrollment (e.g., ranibizumab, bevacizumab, aflibercept, conbercept). 8. Known allergy to the drug planned to be used in the study.